A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/23/2006	US20060264452 Analgesics; immunomodulators and for treatment of drug dependence; for example, 5'-Bromo-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5 alpha -epoxypyrido[2',3':6,7]morphinan
11/23/2006	US20060264451 CXCR4 antagonists for the treatment of HIV infection
11/23/2006	US20060264450 Such as (S)-4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2-oxo-5-methyl-oxazolidin-3-yl)ethyloxy]-7-methoxy-quinazoline; inhibiting signal transduction by tyrosine kinases; treating tumoral diseases and benign prostatic hyperplasia, and diseases of lungs and respiratory tract
11/23/2006	US20060264449 Compounds for modulation of kinesins as anticancer agents with administering
11/23/2006	US20060264448 Such as 6-Amino-9-benzyl-8-oxo-8,9-dihydro-7H-purine-2-carboxylic acid cyclopropylmethyl-amide for treatment of viral infections and immune or inflammatory disorders, including those involving Toll-Like Receptors; Hepatitis, arthritis, asthma, cancer
11/23/2006	US20060264445 Compounds Capable of Activating Cholinergic Receptors
11/23/2006	US20060264444 3-(4-Chlorophenoxy)-5-fluoro-2-methyl-1H-indole-1-acetic acid; asthma and chronic obstructive pulmonary disease (COPD)
11/23/2006	US20060264443 Treatment of rheumatoid arthritis
11/23/2006	US20060264442 Methods for the treatment of ocular and neurodegenerative conditions in a mammal
11/23/2006	US20060264441 N-[(1-azabicyclo[2.2.2]oct-2-yl)arylmethyl]-benzamide derivatives; psychological, behavioral, eating, sexual, sleep, nervous system, and/or neurodegenerative disorders; drug abuse, alcoholism, schizophrenia, psychoses, Parkinson*s disease, epilepsy; analgesics, antidepressants, anxiolytic agents
11/23/2006	US20060264440 Pyrazoles and methods of making and using the same
11/23/2006	US20060264439 Inhibitors of polo-like kinase-1
11/23/2006	US20060264438 Pyrrolotriazine compounds as kinase inhibitors
11/23/2006	US20060264437 Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-F]quinoline as 5-HT1A antagonists
11/23/2006	US20060264436 Method of Treating a Psychotic Disorder
11/23/2006	US20060264435 Novel compounds
11/23/2006	US20060264434 Chemokine receptor binding heterocyclic compounds
11/23/2006	US20060264433 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
11/23/2006	US20060264432 Adenosine A1, A2a, and A2b receptor ligands; coupling the 2-mercapto-3,5-dicyano-4-aryl-6-aminopyridine to a substituted alkyl or alkenyl compound; antiischemic agents; cardiovascular disorders
11/23/2006	US20060264431 P38 inhibitors and methods of use thereof
11/23/2006	US20060264430 Pyrazole derivative
11/23/2006	US20060264429 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
11/23/2006	US20060264428 Tri-, tetra-substituted-3-aminopyrrolidine derivative
11/23/2006	US20060264427 DNA-PK inhibitors
11/23/2006	US20060264426 Antiinfective agent, antiproliferation agent, antiinflammatory agent or prokinetics
11/23/2006	US20060264425 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
11/23/2006	US20060264424 Arylsulfonamidobenzylic compounds
11/23/2006	US20060264423 Methylene Blue Therapy of Viral Disease
11/23/2006	US20060264422 Use of taurolidine as enhancer of the complement system
11/23/2006	US20060264421 Conversion process for 2,3-benzodiazepine enantiomers
11/23/2006	US20060264420 Tteating cell proliferation disease by modulation of kinesin and treatment of cancer
11/23/2006	US20060264419 Substituted pyrazoles
11/23/2006	US20060264418 6-(2,2,2-Trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist
11/23/2006	US20060264417 N-(3-tetrahydrobenzodiazepinonyl)succamides: 2R,3S)N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide; inhibit production of A beta -peptide, preventing neurological amyloid deposits; Alzheimer's disease
11/23/2006	US20060264416 Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
11/23/2006	US20060264415 Inhibitors of histone deacetylase
11/23/2006	US20060264414 Fluorous 2,2'-bipyridines and fluorinated biphasic sysems for ligand design
11/23/2006	US20060264413 Method and composition for inhibiting cell proliferation and angiogenesis
11/23/2006	US20060264412 Carbonylation; hydrogenation; for preparation of eplerenone
11/23/2006	US20060264411 Control of biofilm formation
11/23/2006	US20060264410 useful in treating biological disorders mediated by vitamin D receptors and/or in treating disorders where a rise in serum calcium is undesirable
11/23/2006	US20060264409 Ulcerative colitis and Crohn's disease; 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine)
11/23/2006	US20060264408 Sod minic multifunctional compounds for treating inflammatory bowel disease
11/23/2006	US20060264407 Useful as cosmetics and quasi drugs; L-ascorbic acid-2-phosphate ester
11/23/2006	US20060264406 Mono-lysine salts of azole compounds
11/23/2006	US20060264405 Dimethylphosphinorapamycin; treating cancer; improved therapeutic index, pharmacokinetics, and formulatability
11/23/2006	US20060264404 Therapeutic phosphonate compounds
11/23/2006	US20060264403 phosphoric acid mono-[2-hydroxymethyl-4-(4-octyl-phenyl)-2-(1-oxo-1,3-dihydro-isoindol-2-yl)-butyl] ester; disorders mediated by lymphocytes interactions like transplant rejection, graft versus host disease, autoimmune diseases; binding affinity to Sphingosine-1-phosphate(S1P) receptors
11/23/2006	US20060264401 preferential dipeptidyl peptidase-IV inhibitors such as (2R)-1-{2-[(3S)-Pyrrolidin- 3-methyl-3-ylamino]- acetyl}-pyrrolidine-2- boronic acid, used as antidiabetic agents
11/23/2006	US20060264400 Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
11/23/2006	US20060264398 Purinergic modulation of smell
11/23/2006	US20060264397 Compositions and methods for targeting cancer cells
11/23/2006	US20060264393 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases
11/23/2006	US20060264391 Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
11/23/2006	US20060264390 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
11/23/2006	US20060264389 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
11/23/2006	US20060264388 Method for treating liver cancer by intrahepatic administration of nemorubicin
11/23/2006	US20060264387 Ketolides having a fused five-membered lactone ring and a substituted cladinose sugar attached to the macrolide ring; erythromycin derivatives; improved activity towards bacteria resistant to erythromycin, clindamycin and tetracycline; antiinflammatory agents; phosphodiesterase inhibitors
11/23/2006	US20060264386 Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
11/23/2006	US20060264385 like antiinfective (bactericide, fungicide, parasiticide, viricide), and antiproliferative, antiinflammatory, and prokinetic agents; 1,2,3-triazole-oxazolidine-phenyl- derivatives; effective against strains of cells or organisms that have developed drug resistance; administering orally
11/23/2006	US20060264384 Compositions and methods for treatment for neoplasms
11/23/2006	US20060264383 Morning glory-derived anticancer agents, and novel ipomoeassin compounds
11/23/2006	US20060264382 6"-Amino-6"-deoxygalactosylceramides
11/23/2006	US20060264381 Methods of treating obsessive compulsive disorder
11/23/2006	US20060264380 Compounds and Methods for Promoting Angiogenesis
11/23/2006	US20060264375 Elastin protective polyphenolics and methods of using the same
11/23/2006	US20060264372 Process for the synchronization of ovulation for timed breeding without heat detection
11/23/2006	US20060264359 inducing eosinophil apoptosis; Pin1 inhibitor is juglone
11/23/2006	US20060264357 Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
11/23/2006	US20060264356 Increased or improved bioavailability of the active agents for oral, intracolonic, pulmonary, and other routes of administrations
11/23/2006	US20060264354 Cop 1 for treatment of inflammatory bowel diseases
11/23/2006	US20060264353 Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
11/23/2006	US20060263852 Asp2
11/23/2006	US20060263821 In vitro model for priocidal activity
11/23/2006	US20060263801 Methods of high-throughput screening for internalizing antibodies
11/23/2006	US20060263781 Regulation of cell surface proteins
11/23/2006	US20060263772 Identification of anti-hiv compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid
11/23/2006	US20060263455 Composition for preventing urinary system infections
11/23/2006	US20060263453 Methods and compositions for modulating glutamate dehydrogenase
11/23/2006	US20060263452 Topical composition containing essential oils
11/23/2006	US20060263447 Treating pulmonary disorders with gaseous agent causing repletion of GSNO
11/23/2006	US20060263446 Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same
11/23/2006	US20060263444 Antimicrobial composition
11/23/2006	US20060263439 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
11/23/2006	US20060263437 Pharmaceutical microspheres containing valproic acid for oral administration
11/23/2006	US20060263436 once daily dosage form of itraconazole independent of food intake; melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling
11/23/2006	US20060263434 Combinations and modes of administration of therapeutic agents and combination therapy
11/23/2006	US20060263431 Opioid Sustained Release Formulation
11/23/2006	US20060263428 Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
11/23/2006	US20060263427 Quinine formulations
11/23/2006	US20060263426 Oral administration form for pyridin-2-ylmethysulfinyl-1h-bezimidazoles
11/23/2006	US20060263425 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
11/23/2006	US20060263424 Pharmaceutical compositions comprising clavulanic acid
11/23/2006	US20060263422 Pharmaceutical composition containing decoy and use of the same
11/23/2006	US20060263421 Transdermal Method and Patch for Nausea
11/23/2006	US20060263419 Transdermal therapeutic system for Parkinson's Disease
11/23/2006	US20060263415 Production of beta-glucans and mannans
11/23/2006	US20060263409 Treatment of ocular disease
11/23/2006	US20060263407 Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants
11/23/2006	US20060263401 Packet of spherical particles containing sustained release antibiotic and aqueous solution of thrombin; mixture of biocompatible polymer and gel; in situ wound healing agents

1 ... 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 ... 7860